The Role of Macrolides for the Management of Community-Acquired Pneumonia and Pneumonia by the Novel Coronavirus SARS-CoV-2 (COVID-19): A Position Paper by Four Medical Societies from Greece.
Azithromycin
COVID-19
Clarithromycin
Community-acquired pneumonia
Immunomodulation
Journal
Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499
Informations de publication
Date de publication:
16 Jun 2021
16 Jun 2021
Historique:
received:
13
03
2021
accepted:
26
05
2021
entrez:
22
6
2021
pubmed:
23
6
2021
medline:
23
6
2021
Statut:
aheadofprint
Résumé
In light of the accumulating evidence for survival benefit coming from the use of macrolides for community-acquired pneumonia (CAP), a group of experts from the field of internal medicine and infectious diseases frame a position statement on the use of macrolides for the management of bacterial CAP and for infection by the novel coronavirus (COVID-19). The statement is framed taking into consideration existing publications and own research experience. The main content of this statement is that the combination of one β-lactam and a macrolide should be the first treatment of choice for patients with severe bacterial CAP. Severity is assessed as scoring 2 or more points on the CURB65 scoring system of severity or as pneumonia severity index III to V or C-reactive protein more than 150 mg/l; the suggested macrolide is either azithromycin or clarithromycin. The experts also suggest that in COVID-19 pneumonia, the combination of one β-lactam and a macrolide should be reserved only when there is strong suspicion of bacterial co-infection.
Identifiants
pubmed: 34155472
doi: 10.1007/s40121-021-00471-1
pii: 471
doi:
Banques de données
figshare
['10.6084/m9.figshare.14672379']
Types de publication
Journal Article
Langues
eng
Pagination
1-15Informations de copyright
© The Author(s) 2021.
Références
Arch Pharm Res. 2020 May;43(5):526-539
pubmed: 28861755
Respir Med. 2018 Jul;140:115-121
pubmed: 29957272
J Antimicrob Chemother. 2014 Jun;69(6):1441-6
pubmed: 24535276
BMC Emerg Med. 2015 Oct 13;15:29
pubmed: 26464225
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67
pubmed: 31573350
Am J Respir Cell Mol Biol. 2020 Nov;63(5):707-709
pubmed: 32857620
Cell Prolif. 2021 Jan;54(1):e12953
pubmed: 33211371
J Infect Chemother. 2019 Dec;25(12):1012-1018
pubmed: 31227381
J Antimicrob Chemother. 2016 Oct;71(10):2767-81
pubmed: 27494903
Int J Antimicrob Agents. 2020 Jan;55(1):105836
pubmed: 31704213
Infect Dis (Lond). 2018 Jan;50(1):13-20
pubmed: 28699429
Lancet. 2020 Oct 3;396(10256):959-967
pubmed: 32896292
Respirology. 2018 May;23(5):526-534
pubmed: 29239493
J Intern Med. 2015 Aug;278(2):174-84
pubmed: 25529395
Infect Chemother. 2018 Dec;50(4):328-339
pubmed: 30600656
J Glob Antimicrob Resist. 2019 Mar;16:260-261
pubmed: 30797089
Expert Opin Drug Saf. 2019 Nov;18(11):1055-1063
pubmed: 31500468
Antiviral Res. 2017 Aug;144:48-56
pubmed: 28535933
J Antimicrob Chemother. 2019 Aug 1;74(Suppl 4):iv39-iv47
pubmed: 31505644
BMC Pulm Med. 2020 Jun 5;20(1):160
pubmed: 32503515
Expert Rev Anti Infect Ther. 2021 Feb;19(2):147-163
pubmed: 32853038
Respirology. 2016 Oct;21(7):1193-200
pubmed: 27338144
Respiration. 2017;93(6):441-450
pubmed: 28449003
Clin Microbiol Infect. 2020 Oct 10;:
pubmed: 33049414
Int J Clin Pract. 2021 Feb;75(2):e13667
pubmed: 33448574
Clin Microbiol Infect. 2018 Feb;24(2):146-151
pubmed: 28648859
JAMA Intern Med. 2014 Dec;174(12):1894-901
pubmed: 25286173
Respirology. 2019 Dec;24(12):1212-1219
pubmed: 30989728
J Antimicrob Chemother. 2014 Apr;69(4):1111-8
pubmed: 24292991
Chest. 2019 Apr;155(4):795-804
pubmed: 30471269
Antimicrob Agents Chemother. 2016 May 23;60(6):3640-6
pubmed: 27044546
Stem Cell Rev Rep. 2020 Jun;16(3):434-440
pubmed: 32307653
Int J Antimicrob Agents. 2020 Oct;56(4):106143
pubmed: 32853672
N Engl J Med. 2020 Nov 19;383(21):2041-2052
pubmed: 32706953
Infect Drug Resist. 2018 Nov 26;11:2461-2469
pubmed: 30538512